Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone650-243-6300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$71.95 million
Profitability
Miscellaneous
Employees246
OptionableOptionable
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte Inc (NASDAQ:VCYT) announced its quarterly earnings results on Monday, October, 29th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.13. The biotechnology company earned $23.47 million during the quarter, compared to analyst estimates of $21.52 million. Veracyte had a negative return on equity of 65.73% and a negative net margin of 33.00%. View Veracyte's Earnings History.
When is Veracyte's next earnings date?
What guidance has Veracyte issued on next quarter's earnings?
Veracyte updated its FY 2018 earnings guidance on Monday, October, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $90-91 million, compared to the consensus revenue estimate of $88.09 million.
What price target have analysts set for VCYT?
4 brokerages have issued 1 year price targets for Veracyte's stock. Their forecasts range from $11.00 to $17.00. On average, they expect Veracyte's share price to reach $13.4333 in the next year. This suggests that the stock has a possible downside of 22.3%. View Analyst Price Targets for Veracyte.
What is the consensus analysts' recommendation for Veracyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.
Has Veracyte been receiving favorable news coverage?
Media coverage about VCYT stock has trended neutral recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Veracyte earned a coverage optimism score of 0.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Are investors shorting Veracyte?
Veracyte saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,150,033 shares, an increase of 58.1% from the December 14th total of 1,359,751 shares. Based on an average daily trading volume, of 311,061 shares, the short-interest ratio is currently 6.9 days. Approximately 7.0% of the company's shares are sold short. View Veracyte's Current Options Chain.
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include Genomic Health (GHDX), InVitae (NVTA), CareDx (CDNA), Natera (NTRA), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), Fulgent Genetics (FLGT), PotNetwork (POTN), OpGen (OPGN), First Choice Healthcare Solutions (FCHS), CBA Florida (CBAI) and Cancer Genetics (CGIX).
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
- Mr. Christopher M. Hall, Pres & COO (Age 50)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific Officer & Head of Scientific, Clinical and Medical Affairs Department (Age 60)
- Mr. Ashish Kheterpal, Chief Information Officer
Who are Veracyte's major shareholders?
Veracyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include Meeder Asset Management Inc. (0.02%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Institutional Ownership Trends for Veracyte.
Which institutional investors are selling Veracyte stock?
VCYT stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall and Jesse I Treu. View Insider Buying and Selling for Veracyte.
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $17.28.
How big of a company is Veracyte?
Veracyte has a market capitalization of $700.51 million and generates $71.95 million in revenue each year. The biotechnology company earns $-31,000,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Veracyte employs 246 workers across the globe.
What is Veracyte's official website?
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (NASDAQ VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
